Menopause and Hot Flashes: Important FDA Warning on Veozah's Side Effects

Menopause Treatments: Understanding Veozah

Menopause often brings uncomfortable symptoms like hot flashes, and Veozah (fezolinetant) has emerged as a nonhormonal treatment option. Approved by the FDA in May 2023, this medication works by blocking the neurokinin 3 receptor to balance hormones and regulate body temperature. However, serious side effects, particularly liver injury, have been highlighted in the latest healthcare news.

FDA Warning on Liver Injury

Recently, the FDA issued a warning regarding Veozah's potential to cause rare but severe liver injuries. Following a postmarketing review, it was determined that patients may experience elevated liver blood test values and symptoms indicating liver damage.

Side Effects and Precautions for Patients

• Common Side Effects: Stomach pain, diarrhea, difficulty sleeping, and hot flashes.
• Severe Signs: Fatigue, jaundice, unusual itching, and dark urine.

Patients should cease taking Veozah immediately if they experience symptoms of liver injury and contact their healthcare provider for guidance.

Recommendations for Healthcare Professionals

1. Conduct liver function tests before prescribing Veozah.
2. Monitor liver health monthly for the first three months of treatment.
3. Inform patients about the risks and necessary precautions.

The FDA emphasizes the importance of understanding medication side effects and reporting any adverse events through the FDA MedWatch program. Ensuring patient safety and health should remain a priority in treatment discussions.